The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2013Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease
Objective/Rationale:
Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection. STATegics has discovered small... -
Aligning Science Across Parkinson's, 2021Understanding and Manipulating Cellular and Circuit-level Vulnerability to Neurodegeneration in Parkinson’s Disease
Study Rationale:
Many people with Parkinson’s disease develop untreatable cognitive symptoms, including problems with attention, decision-making, and dementia at late stages of the disease, due to... -
Edmond J. Safra Movement Disorders Research Career Development Award, 2024Towards a Better Understanding of Treatment-refractory Gait Issues in Parkinson’s Disease
Study Rationale: Freezing of gait (FOG) is a sudden arrest of gait despite the intention to continue walking, often while a person is turning, walking in a confined space or is in a situation that...
-
Rapid Response Innovation Awards, 2009Plasma Biomarker Screen for Neurodegeneration and Signaling Proteins
Objective/Rationale:
The cells and tissues of the body can “communicate” with one another using small secreted proteins that can be found in the blood. There are several hundred of these cellular... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Fisetin and Derivatives as Neuroprotective Drugs for the Treatment of Parkinson's Disease
Objective/Rationale:
Glutathione (GSH) is an antioxidant produced naturally by cells thereby providing them with a defense against oxidative stress. There is good evidence that GSH levels decrease in... -
MJFF Research Grant, 2010Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup
Objective/Rationale:
Ashkenazi Jewish PD patients in Israel have a 14% chance of carrying the G2019S LRRK2 mutation and 18% of carrying mutations in the GBA gene. Little is known on the association...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.